Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

02 Jun 2026 - 04 Jun 2026
17 Jun 2026 - 19 Jun 2026
05 Oct 2026 - 06 Oct 2026

Drug Reduces Lesions that Precede Prostate Cancer

By HospiMedica staff writers
Posted on 05 Nov 2001
In clinical trials, the drug toremifene (Acapodene) has demonstrated the ability to eliminate 72% of the lesions that precede prostate cancer and lower the incidence of prostate cancer by 50%. More...
A larger-scale clinical trial is now under way.

High-grade premalignant lesions, or prostatic intraepithelial neoplasia (PIN), indicate a high risk of prostate cancer, with 30-50% of men with a high-grade PIN developing cancer within the next three years. Currently, there are no treatments for high-grade PIN.
GTx, Inc., a biopharmaceutical company in Memphis (TN, USA), has licensed toremifene from Orion Pharma, a Finnish pharmaceutical company. Orion Pharma's toremifene (Fareston) was previously cleared by the US Food and Drug Administration (FDA) for the treatment of advanced breast cancer.

"Acapodene has some very exciting possibilities for the treatment of prostate cancer through an avenue that hasn't been explored before now—prevention,” said John Seigne, M.D., assistant professor of surgery at Moffitt Cancer Center and Research Institute in Tampa (FL, USA) and lead investigator of the study.

Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gas Analyzer
GE SAM
Pediatric Mask
Respire SOFT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The Elyra TFL System uses thulium fiber laser technology for efficient stone dusting and reduced stone migration, with an air-cooled design for quieter, more compact operation (photo courtesy of BD

BD Launches Elyra Laser Platform for Kidney Stone and Soft Tissue Procedures

BD (Becton, Dickinson and Company) has introduced the Elyra Thulium Fiber Laser (TFL) System, an advanced laser platform developed to complete its kidney stone care portfolio for urology teams.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.